Walleye Trading
KRYS icon

Walleye Trading’s Krystal Biotech KRYS Stock Holding History

Walleye Trading’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,700
Closed -$266K – 4388
2024
Q4 		$266K Sell
1,700
-1,500
-47% -$266K ﹤0.01% 3070
2024
Q3 		$582K Buy
+3,200
New +$617K ﹤0.01% 2429
2024
Q2 		– Sell
-1,200
Closed -$214K – 4625
2024
Q1 		$214K Buy
+1,200
New +$167K ﹤0.01% 3385
2023
Q3 		– Sell
-700
Closed -$82.2K – 5184
2023
Q2 		$82.2K Sell
700
-8,600
-92% -$878K ﹤0.01% 3818
2023
Q1 		$745K Buy
+9,300
New +$731K ﹤0.01% 2470
2022
Q1 		– Sell
-200
Closed -$14K – 5622
2021
Q4 		$14K Buy
+200
New +$11.6K ﹤0.01% 5026
2021
Q3 		– Sell
-3,700
Closed -$252K – 5476
2021
Q2 		$252K Buy
+3,700
New +$258K ﹤0.01% 3693

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Walleye Trading's KRYS Position: Q1 2025 in Review

Walleye Trading sold out of Krystal Biotech (KRYS) in Q1 2025, closing a stake of 393 shares — an estimated $61.6K sold.

Walleye Trading first reported a position in KRYS in Q2 2021 and held it in 2 quarters. The position peaked at $61.6K in Q4 2024. 299 funds tracked by Wall St. Rank hold KRYS as of Q1 2025.

  • Walleye Trading reported no remaining Krystal Biotech position as of Q1 2025 after selling out during the quarter.
  • Walleye Trading sold 393 Krystal Biotech shares in Q1 2025, an estimated $61.6K.
  • Walleye Trading first reported a position in Krystal Biotech in Q2 2021 and held it in 2 quarters.
  • Walleye Trading's Krystal Biotech position peaked at $61.6K in Q4 2024.
  • 299 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2025.

Based on Walleye Trading's 13F filing for Q1 2025, filed 14 May 2025.